RCUS - Arcus Biosciences, Inc.
| Previous Close | 15.95 |
| Open | 15.95 |
| Bid | 15.87 x 800 |
| Ask | 18.00 x 2200 |
| Day's Range | 15.51 - 18.44 |
| 52 Week Range | 6.30 - 18.44 |
| Volume | 761,623 |
| Avg. Volume | 177,914 |
| Market Cap | 788.708M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | Aug 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.71 |
- Business Wire
Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.
- Simply Wall St.
Introducing Arcus Biosciences (NYSE:RCUS), The Stock That Dropped 10% In The Last Year
While not a mind-blowing move, it is good to see that the Arcus Biosciences, Inc. (NYSE:RCUS) share price has gained...
- Insider Monkey
Is Arcus Biosciences, Inc. (NYSE:RCUS) A Good Stock To Buy?
Does Arcus Biosciences, Inc. (NYSE:RCUS) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
- Insider Monkey
Arcus Biosciences, Inc. (RCUS): Hedge Funds Are Snapping Up
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
- Zacks
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus
Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.
- Simply Wall St.
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
- Simply Wall St.
Have Insiders Been Buying Arcus Biosciences, Inc. (NYSE:RCUS) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Zacks
Infinity Initiates 2 Studies for Lead Candidate IPI-549
Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.
- Zacks
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -72.97% and -61.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.
- Zacks
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q2 Earnings Expected to Decline
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
If You Had Bought Arcus Biosciences (NYSE:RCUS) Stock A Year Ago, You'd Be Sitting On A 30% Loss, Today
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
- Benzinga
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
- Business Wire
Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of the Company’s global commercial strategy and operations as the Company works to ensure that it most efficiently leverages the clinical and market development opportunities for its therapeutic candidates.
